v3.26.1
Revenue
 3 Months Ended
Mar. 31, 2026
Revenue from Contract with Customer [Abstract]  
Revenue REVENUE
The Company develops, manufactures and sells devices designed for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves. These devices are marketed to a broad base of medical centers globally and primarily used by cardiothoracic and thoracic surgeons. The Company recognizes revenue when control of promised goods is transferred to customers in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods.
United States revenue by product type is as follows:
Three Months Ended
March 31,
20262025
Open ablation $39,080$33,308
Minimally invasive ablation 6,3868,480
Pain management22,35917,270
Appendage management48,38042,091
Total United States$116,205$101,149
International revenue by product type is as follows:
 Three Months Ended
March 31,
 20262025
Open ablation $9,516$8,995
Minimally invasive ablation 1,9132,013
Pain management1,9901,789
Appendage management11,6259,674
Total International $25,044$22,471
Revenue attributed to customer geographic locations is as follows:
Three Months Ended
March 31,
20262025
United States$116,205$101,149
Europe16,07214,198
Asia Pacific7,0786,784
Other International1,8941,489
Total International25,04422,471
Total Revenue$141,249$123,620